Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma With 6 Months Follow-up
NCT00988455 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28
Last updated 2009-10-02
Summary
The purpose of this study is to evaluate the efficacy of photodynamic therapy (PDT)in treatment of Basal cell carcinoma (BCC) and recurrence rate after 6 months.
Conditions
Interventions
- RADIATION
-
photodynamic therapy
5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
Sponsors & Collaborators
-
Shahid Beheshti University of Medical Sciences
lead OTHER
Principal Investigators
-
zohreh Tehranchi-nia, assist.prof. · skin research center
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-01-31
- Primary Completion
- 2009-03-31
- Completion
- 2009-08-31
More Related Trials
-
Effectiveness of Stereotactic RadioTherapy in Solid Primary Inoperable and Oligometastatic Cancer
NCT03461822 ·Status: UNKNOWN
-
SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE
NCT02221778 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic Patients
NCT05229575 ·Status: UNKNOWN ·Phase: NA
-
Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer
NCT03408665 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
NCT03989596 ·Status: UNKNOWN ·Phase: PHASE2
-
Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases
NCT02159742 ·Status: ACTIVE_NOT_RECRUITING
-
The Use of Photobiomodulation in the Management of Radiodermatitis in Patients in Palliative Care. A Prospective Study.
NCT05561803 ·Status: WITHDRAWN
-
Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer
NCT01934478 ·Status: COMPLETED
-
Palliative Short Course Radiotherapy for Advanced Thoracic Cancer
NCT03465553 ·Status: COMPLETED ·Phase: NA
-
Electronic Brachytherapy for the Treatment of NMSC
NCT01016899 ·Status: COMPLETED
-
Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
NCT01215500 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of SBRTand Repeat TACE for HCC
NCT03326375 ·Status: UNKNOWN ·Phase: NA
-
A Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma
NCT05294120 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases
NCT03391362 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Retrospective Analysis to Evaluate Long Term Outcomes of SCC Patients Previously Treated With Alpha DaRT
NCT05125354 ·Status: COMPLETED
-
The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of Lung in the Treatment Course of Radiation Therapy
NCT00751543 ·Status: UNKNOWN ·Phase: NA
-
Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect
NCT03825510 ·Status: COMPLETED ·Phase: PHASE2
-
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
NCT03812289 ·Status: TERMINATED ·Phase: NA
-
Coagulation System In STereotactic Radiotherapy Of NSCLC
NCT03893461 ·Status: UNKNOWN
-
Radiotherapy for Extracranial Oligometastatic Breast Cancer
NCT04646564 ·Status: RECRUITING ·Phase: PHASE3
-
Multimodality- Adapted Dose Modification in Head and Neck Cancer Radiation Therapy 
NCT04933357 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study of Electronic Brachytherapy for Cutaneous Basal Cell Carcinoma
NCT02939027 ·Status: COMPLETED ·Phase: NA
-
SBRT for Extra-cranial Oligorecurrent Tumor
NCT02410187 ·Status: UNKNOWN ·Phase: PHASE2
-
Stereotactic Body Radiotherapy for Liver Tumors
NCT01347333 ·Status: COMPLETED ·Phase: NA
-
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
NCT06349837 ·Status: RECRUITING ·Phase: PHASE1